Getting Up to Speed: Rapid Pathogen and Antimicrobial Resistance Diagnostics in Sepsis
Microorganisms · 03.09.2024 · 12 (9) · 1824
DOI: 10.3390/microorganisms12091824 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microorganisms, online erschienen am 03.09.2024. Verfasst von Mariana P Liborio und 3 weiteren Autor:innen. Beteiligte Einrichtung: UQ Centre for Clinical Research, The University of Queensland, Herston, QLD 4029, Australia. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 173 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Queensland.
Themen: Sepsis
Abstract (Originalsprache)
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Time to receive effective therapy is a primary determinant of mortality in patients with sepsis. Blood culture is the reference standard for the microbiological diagnosis of bloodstream infections, despite its low sensitivity and prolonged time to receive a pathogen detection. In recent years, rapid tests for pathogen identification, antimicrobial susceptibility, and sepsis identification have emerged, both culture-based and culture-independent methods. This rapid narrative review presents currently commercially available approved diagnostic molecular technologies in bloodstream infections, including their clinical performance and impact on patient outcome, when available. Peer-reviewed publications relevant to the topic were searched through PubMed, and manufacturer websites of commercially available assays identified were also consulted as further sources of information. We have reviewed data about the following technologies for pathogen identification: fluorescence in situ hybridization with peptide nucleic acid probes (Accelerate PhenoTM), microarray-based assay (Verigene®), multiplex polymerase chain reaction (cobas® eplex, BioFire® FilmArray®, Molecular Mouse, Unyvero BCU SystemTM), matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (Rapid MBT Sepsityper®), T2 magnetic resonance (T2Bacteria Panel), and metagenomics-based assays (Karius©, DISQVER®, Day Zero Diagnostics). Technologies for antimicrobial susceptibility testing included the following: Alfed 60 ASTTM, VITEK® REVEALTM, dRASTTM, ASTar®, Fastinov®, QuickMIC®, ResistellTM, and LifeScale. Characteristics, microbiological performance, and issues of each method are described, as well as their clinical performance, when available.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- UQ Centre for Clinical Research, The University of Queensland, Herston, QLD 4029, Australia.
- Herston Infectious Disease Institute, Metro North, QLD Health, Herston, QLD 4029, Australia.
- Central Microbiology, Pathology Queensland, Royal Brisbane and Women's Hospital, Herston, QLD 4006, Australia.
- Infection Management and Prevention Service, Queensland Children's Hospital, Brisbane, QLD 4101, Australia.
ORCID-Profile: Mariana P Liborio, Patrick N A Harris, Chitra Ravi, Adam D Irwin
Förderung
- University of Queensland
Zitieren
APA
Liborio, M. P., Harris, P. N. A., Ravi, C., & Irwin, A. D. (2024). Getting Up to Speed: Rapid Pathogen and Antimicrobial Resistance Diagnostics in Sepsis. Microorganisms, 12(9), 1824. https://doi.org/10.3390/microorganisms12091824
Vancouver
Liborio MP, Harris PNA, Ravi C, Irwin AD. Getting Up to Speed: Rapid Pathogen and Antimicrobial Resistance Diagnostics in Sepsis. Microorganisms. 2024;12(9):1824. doi:10.3390/microorganisms12091824
BibTeX
@article{Liborio2024,
author = {Liborio, Mariana P and Harris, Patrick N A and Ravi, Chitra and Irwin, Adam D},
title = {Getting Up to Speed: Rapid Pathogen and Antimicrobial Resistance Diagnostics in Sepsis},
journal = {Microorganisms},
year = {2024},
volume = {12},
number = {9},
pages = {1824},
doi = {10.3390/microorganisms12091824}
}
EUVIMED